Generic Name and Formulations:
Ezogabine 50mg, 200mg, 300mg, 400mg; tablets.
Company:
GlaxoSmithKline Pharmaceuticals
Adjunctive treatment of partial-onset seizures in patients ≥18yrs old.
Swallow whole. Give in 3 equally divided doses daily. ≥18yrs: initially 300mg/day for 1 week; titrate at weekly intervals by no more than 150mg/day up to a maintenance dose of 600–1200mg/day. Elderly (>65yrs) or hepatic impairment (Child-Pugh 7–9): initially 150mg/day; max 750mg/day. Renal impairment (CrCl <50mL or ESRD on dialysis) or hepatic impairment (Child-Pugh >9): initially 150mg/day; max 600mg/day. See literature.
<18yrs: not established.
Potassium channel opener.
Increased risk of urinary retention; monitor closely in patients with BPH, cognitively impaired, or concomitant medications that may affect voiding (eg, anticholinergics). Monitor for neuropsychiatric symptoms (eg, confusional state, psychosis, hallucinations), dizziness, somnolence. Monitor QT interval in patients with known prolonged QT interval, CHF, ventricular hypertrophy, hypokalemia, or hypomagnesemia. Monitor for emergence or worsening of depression, suicidal thoughts/behavior, and/or unusual changes in mood or behavior. Avoid abrupt cessation; withdraw gradually over at least 3 weeks. Pregnancy (Cat. C). Nursing mothers: not recommended.
Caution with drugs known to increase the QT interval. Plasma levels reduced by concomitant phenytoin or carbamazepine; consider increasing ezogabine dose. May potentiate digoxin; monitor. Increased exposure with alcohol; caution. May interfere in clinical lab assays of serum and urine bilirubin.
Dizziness, somnolence, fatigue, confusional state, vertigo, tremor, abnormal coordination, diplopia, attention disturbance, memory impairment, asthenia, blurred vision, gait disturbance, aphasia, dysarthria, balance disorder.
Tabs—90